CARY, N.C., Oct. 20, 2021 -- Two North Carolina companies, analytics leader SAS and venture investment firm Pappas Capital, are joining forces to help advance the state as a global...
Anthera advances global development strategy for varespladib with the initiation of FRANCIS trial
News | 08. 25. 2008
Anthera Pharmaceuticals
SAN MATEO, CA – August 25, 2008 – Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.
